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Abstract
Background: Oral anticoagulation therapy is widely used to reduce the risks of thromboembolism. However, the
therapy increases the risk of hemorrhage during the surgical procedures. The aim of this meta-analysis was to
evaluate the bleeding risk of patients continuing or discontinuing oral anticoagulant therapy while undergoing
dental extractions.
Methods: Six electronic databases, including PubMed, Embase, Cochrane library, Web of Science, China Biology
Medicine disc (CBM), and China National Knowledge Infrastructure (CNKI), were searched in March, 2016. Relevant
articles were screened by two independent reviewers under our inclusion criteria. Quality was evaluated using the
Cochrane Collaboration risk of bias tool. Meta-analyses were conducted with fixed and random effects models as
appropriate.
Results: Six studies (with a total of 591 patients) were included in our meta-analysis. Our results showed that there
was no significant difference in the bleeding risk between patients continuing or discontinuing oral anticoagulant
therapy while undergoing dental extractions (risk ratio, 1.31; 95 % CI, 0.79, 2.14; P > 0.05). There was also no
significant difference in bleeding risk 1 day (risk ratio, 0.91; 95 % CI, 0.35, 2.37; P > 0.05) and 7 days (risk ratio, 1.47;
95 % CI, 0.83, 2.59; P > 0.05) after the dental extraction.
Conclusion: Under current studies and evidence, it appears that patients continuing oral anticoagulant therapy do
not have an increased risk of bleeding after dental extractions compared to patients who discontinue oral
anticoagulant therapy.
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Background
With the living standard gradually increasing and diet
habits continuously changing, cardiovascular diseases, such
as mechanical heart valve, atrial fibrillation and venous
thromboembolism, have become more and more common.
Millions of people receive oral anticoagulant therapy
(OAT). Used to reduce thrombosis, oral anticoagulation
therapy is one of the most effective prophylactic medica-
tions for preventing life-threatening events [1, 2]. Oral anti-
coagulant drugs mainly include heparin, warfarin and new
oral anticoagulants (NOACs) [3]. Heparin should be ad-
ministered intravenously, and its action is to interfere with
thrombin-antithrombin pathways and reduce fibrin forma-
tion. Warfarin, which is derived from 4-hydroxycoumarin,
is a competitive inhibitor of vitamin K. It is widely used all
over the world [4]. New oral anticoagulants (NOACs) in-
clude factor Xa inhibitors, such as rivaroxaban, apixaban,
and edoxaban, which mainly inhibit the factor Xa activity of
the prothrombinase complex in the propagation phase, and
factor IIa inhibitors such as dabigatran. Although their ad-
vantages included a rapid onset and a short half-life,
NOACs are still not ready to completely replace conven-
tional anticoagulants [3].
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However, with the wide use of oral anticoagulant ther-
apy (OAT), a major disadvantage of OAT that should re-
ceive more attention, is the increased risk of hemorrhage
during surgical procedures. OATs are frequently pre-
scribed to elder patients, who also have a higher demand
for dental extraction caused by caries, periodontitis or
other dental diseases. So, the problem of postoperative
bleeding becomes a major concern for the dentist.
Whether to continue or discontinue OAT has become a
strong controversy. If OAT is continued, there is a high
risk of bleeding, and if OAT is discontinued, the thrombo-
embolic complications are potentially deadly.
Discontinuing OAT 2 or 3 days before oral surgery has
been a widely used strategy for managing patients on war-
farin [5, 6]. However,the risk of postoperative bleeding ap-
parently does not decrease, and the thromboembolic risk
increases [7]. There have been documented incidences of
thromboembolic events when warfarin was stopped prior
to a dental procedure or a minor oral surgery [8, 9]. Garcia
et al. [10] published the first important prospective study
on the risk of thromboembolism with a short-term inter-
ruption of OAT by reporting that the incidence of
thromboembolism within a 30-day follow-up period was
0.5 %. Though the incidence of thromboembolism is low,
the consequence may be deadly. These thromboembolic
events can have devastating clinical consequences, such as
an embolic stroke, which can result in major disability or
death, or myocardial ischaemia, which can increase risk of
death two to four fold [11]. To solve this problem, some
strategies have been developed in the last few decades.
These strategies include reducing the dose of the anti-
coagulant drugs [12, 13] or bridging it with heparin [14,
15]. These two methods, however, do not completely elim-
inate the risk of thromboembolic events, such as stroke
[9]. Currently, there are a lot of publications suggest that
dental extractions may be carried out with no OAT inter-
ruption if local hemostasis is adequately maintained in the
OAT patients [14, 16–20]. Nevertheless, there is still a
lack of public recognition of the treatment guidelines for
treating these patients. To address this controversy and to
provide evidence-based recommendations, we have com-
pleted a meta-analysis. Articles on randomized controlled
trials (RCTs) or controlled clinical trials (CCTs), including
patients under OAT who undergo dental extractions were
collected, and the postoperative bleeding was compared
between patients who continued OAT and patients who
discontinued OAT.
Methods
The methods for this review were based on the
Cochrane Handbook for Systematic Reviews of Interven-
tions. Throughout the whole process, the studies were
assessed by 2 observers independently, and any disagree-
ment was resolved by discussion.
Database search
A comprehensive search of the PubMed, EMBASE, Web
of Science, Cochrane Library, China Biology Medicine
disc (CBM), and China National Knowledge Infrastruc-
ture(CNKI) databases was conducted in March 2016.
The search strategies for PubMed, EMBASE, Web of
Science and Cochrane Library are shown in Table 1.
Study selection
Two reviewers independently evaluated all of the search
results, and the inclusion criteria were as follows:
1. Study design—studies were designed as randomized
controlled trials (RCTs) or controlled clinical trials
(CCTs)
2. Participants—patients were receiving OAT and
required dental extractions
3. Comparators—the postoperative bleeding between
patients who continue or discontinue OAT.
4. Outcomes—postoperative bleeding (spontaneous
bleeding, induced bleeding and minor bleeding)
The exclusion criteria were as follows:
1. In vitro study (laboratory studies or animal studies),
case reports or letters.
2. Studies on antiplatelet medications.
3. Study outcomes were not clearly reported or the
data could not be used for our meta-analysis.
Data extraction
The following parameters were extracted from each of
the selected studies: the first author, country, year of
publication, design type, patient characteristics, interven-
tion method, and bleeding outcomes. The information is
recorded in the table.
Because there is no accepted standardized definition of
bleeding outcomes for patients undergoing surgical pro-
cedures, we aimed to use the postoperative bleeding to
Table 1 The key words, database and search result
Database Key words Result
Pubmed (oral anticoagulant therapy OR OAT OR
anticoagulant*) AND (dental surgery OR dental
extraction* OR tooth extraction*)
879
Embase (oral anticoagulant therapy OR OAT OR
anticoagulant*) AND (dental surgery OR dental




(oral anticoagulant therapy OR OAT OR
anticoagulant*) AND (dental surgery OR dental




(dental surgery OR dental extraction* OR tooth
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summarize the bleeding outcome after thoroughly read-
ing the included articles. The bleeding outcomes can be
defined as two processes during the follow-up days. One
is the patient’s own perceived bleeding, such as spontan-
eous bleeding that continues for more than 20 min [21]
and oozing from the extraction site [7]. The other bleed-
ing outcome is examined by doctors during the appoint-
ment, and the presence of a solid clot covering the
extraction socket was considered as no bleeding, while
the presence of a fresh clot that shed easily or oozing
blood was considered to be positive bleeding [4].
Risk of bias evaluation
The following seven items were taken into consideration:
(1) allocation concealment, (2) random sequence gen-
eration, (3) blinding of participants and personnel, (4)
blinding of outcome assessment, (5) incomplete out-
come data, (6) selective reporting, and (7) other bias.
The risk of bias for each item was judged as low risk,
high risk, or unclear risk. The overall risk of bias for
each study was evaluated by the following criteria: If the
risk of bias was low for all the items, the study was of
low risk. If one (or more than one) of the risk factors for
bias was high for key items, the study was of high risk. If
one (or more than one) of the risk factors for bias was
unclear, the study had an unclear risk.
Statistical analysis
The bleeding outcomes of the included studies were com-
bined, and a meta-analysis was performed using RevMan
software (version 5.3). Subgroup analyses were performed
once the included studies had the same evaluation inter-
vals. The risk of bleeding for continuing or discontinuing
OAT was expressed as a relative risk (RR) with an associ-
ated 95 % CI. In addition, a chi-square and I2 test were
used to estimate the degree of heterogeneity, with values
of 25, 50, and 75 % corresponding to the low, moderate,
and high heterogeneity, respectively. Substantial hetero-
geneity was defined as a P value <0.05 and I2 >50 %. The
fixed-effects model was applied when I2 <50 %, and the
random-effects model was applied when I2 >50 %.
Results
Literature search
The search process is shown in Fig. 1. There were 968
relevant studies identified during the database search,
and after the exclusion of duplication as well as titles,
abstracts, and full-text screening, finally, we included six
Fig. 1 Study flow diagram
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studies [4, 7, 16, 21–23] in our meta-analysis. Five of the
studies are in English, and the other one [22] is in
Chinese.
Data extraction
The characteristics of the selected six studies are sum-
marized in Tables 2 and 3. The studies were published
between 1993 and 2010. Four of the six studies were
RCT, and the other two were CCT. The total number of
patients under OAT who received dental extractions was
581. The patients were divided into the following two
groups: an OAT continued group and an OAT discon-
tinued group. In the OAT continued group, patients did
not stop their anticoagulant therapy when they needed
dental extractions. In the OAT discontinued group, pa-
tients stopped their anticoagulant therapy 2 or 3 days
before the dental extraction procedure and usually re-
sumed the therapy on the same day. Four of the studies
used warfarin as the anticoagulant drug, one used a vita-
min K inhibitor and one had not report the anticoagu-
lant. The details of the bleeding outcomes are shown in
Table 3. The follow-up ranged from 1 to 7 days. The
bleeding outcomes during patients’ review visits were re-
corded if the article mentioned.
Risk of bias evaluation
The risk of bias summary is shown in Fig. 2. Of the six
included studies, one [21] was judged to have a low risk
of bias because all of the items had a low risk of bias.
Five [4, 7, 16, 22, 23] of the studies were judged to have
a high risk of bias because all of the studies failed to
blind participants and personnel, and three [4, 22, 23]
studies failed to describe the method of randomization
and had no report of the allocation concealment.
Meta-analysis
According to the postoperative bleeding outcomes, we
performed a meta-analysis to compare the bleeding risk
of the OAT continued and OAT discontinued groups.
Six studies were included, with 314 subjects in the
treated group and 277 in the control group.
The incidence of postoperative bleeding was 10.8 %
(34/314) in the OAT continued group and 8.30 % (23/
277) in the OAT discontinued group. A fixed-effects
model was applied because of the low heterogeneity
across the studies. There was no significant difference in
bleeding risk between the OAT continued group and
OAT discontinued group (P = 0.29). The risk ratio was
1.31 and 95 % CI (0.79, 2.14) (Fig. 3).
Subgroup analyses were performed when three or
more studies recorded the bleeding incidence using the
same evaluation intervals. Two time points (1 and 7 days
after the operation) fit the criteria. Three studies [7, 21,
22], with 115 subjects in the treated group and 96 in the
control group were included in the 1 day subgroup. The
bleeding occurred in 8 of 115 (6.9 %) patients in the
treated group and in 7 of 96 (7.2 %) in the control
group. A fixed-effects model was applied, and there was
no significant difference between the two groups (P =
0.85). The risk ratio was 0.91 and 95 % CI (0.35, 2.37)
(Fig. 4).
Four studies [4, 16, 21, 23], with 214 subjects in the
treated group and 196 in the control group were in-
cluded in the 7 day subgroup. The bleeding occurred in
27 of 214 (12.6 %) patients in the treated group and in
17 of 196 (8.7 %) in the control group. A fixed-effects
model was applied and there was no significant differ-
ence between the two groups (P = 0.19). The risk ratio
was 1.47 and 95 % CI (0.83, 2.59) (Fig. 5).
Discussion
Numerous studies have reported that OAT reduces the
risks of thromboembolism significantly [24, 25]. Other
studies have documented that serious embolic complica-
tions, including death, are three times more likely to
occur in patients whose anticoagulant therapy was inter-
rupted, compared to patients with bleeding complica-
tions associated with anticoagulation [26]. For oral
surgery procedures, no case of lethal postoperative
bleeding in patients who continued OAT has been re-
ported [16, 26], whereas several fatal thromboembolic
events after stopping OAT for dental extractions have
Table 2 Characteristics of included studies
Study Country No.(T/C)a Design Anticoagulants Average age (mean ± SD or mean (range))
Borea (1993) [21] Italy 30(15/15) RCT NRb T: 62.7 ± 6.1 C: 61.1 ± 10
Gaspar (1997) [23] Israel 47(32/15) CCT Vitamin K inhibitor T: 61.1(34–85) C: 53.4(35–72)
Devani (1998) [7] UK 65(33/32) CCT Warfarin T: 62.3(30–82) C: 61.3(32–81)
Evans (2002) [16] UK 109(57/52) RCT Warfarin T: 67(36–92) C: 66 (30–93)
Al-Mubarak (2007) [4] Saudi Arabia 214(110/114) RCT Warfarin T: 51.7 ± 14.7 53.1 ± 13.7
C: 52.3 ± 14.3 48.7 ± 13.1
Duan XQ (2010) [22] China 116(67/49) RCT warfarin T: 59.5 ± 12.6 C: 61.5 ± 11.3
aTtreatment group, continue oral anticoagulant therapy group, C control group, discontinue oral anticoagulant therapy group
bNRnot report
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occurred [8, 27]. Nevertheless, there is still a lack of con-
sensus regarding preoperative alteration of the anti-
coagulant regimen to prepare OAT patients for dental
extractions.
Summary of results
The results of our meta-analysis revealed that patients
continuing oral anticoagulant therapy do not have an in-
creased risk of bleeding after dental extraction compared
to patients who discontinue oral anticoagulant therapy.
However, the follow-up dates were not the same be-
tween these studies. One of the studies [22] only re-
ported the first day bleeding outcome, and one study [7]
followed-up for 5 days with a detailed record of everyday
situations. The other four studies [4, 16, 21, 23] followed
up for 7 days after the dental extraction, but three stud-
ies only mentioned the total number of bleeding events
and the remaining one recorded everyday situations.
Subgroup analyses were performed since three of the in-
cluded studies [7, 21, 22] recorded the bleeding outcome
1 day after surgery, and four included studies [4, 16, 21,
23] collected measurements for 7 days after the surgery.
The results were consistent with the previous results.
There was no significant difference in bleeding risk be-
tween the OAT continued group and the OAT discon-
tinued group 1 and 7 days after the surgery. Of all the
studies, none of these patients suffered serious bleeding,
and the bleeding was easily controlled by patients at
home or controlled with local measures during their
visit to the hospital. No thromboembolic event was re-
ported in these studies, whether OAT was continued or
not. However, this outcome could be a result of the
short follow-up period of these studies (from 1 to 7 days),
which made it difficult assess the thromboembolism risk
in patients who discontinued OAT.
All of the 6 included studies came to the conclusion
that OAT patients who do not discontinue the anti-
coagulant medication do not have a significantly higher
risk of postoperative bleeding than OAT patients who
stop the therapy. Some of the studies mentioned the im-
portance of international normalized ratio (INR) and
hemostatic procedures. INR has been used as a
Table 3 Characteristics of included studies
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Fig. 2 Risk of bias of the studies. Summary of risk of bias for included studies. Green indicates a low risk of bias, yellow indicates an unclear risk of
bias, and red indicates a high risk of bias
Fig. 3 Forest plot of the difference of postoperative bleeding between OAT continued or discontinued group
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recommendation for monitoring patients’ oral anti-
coagulant therapy. For stroke prevention in atrial fibrilla-
tion patients, oral anticoagulation therapy that is dose
adjusted to maintain an INR range of 2.0 to 3.0 is associ-
ated with a 64 % reduction in the risk of stroke com-
pared to placebo [28]. And in patients suffering an acute
venous thromboembolism (either deep vein thrombosis
or pulmonary embolism), adjusted-dose OAT use signifi-
cantly reduces the risk of recurrence of thrombotic
events with a target INR range of 2.0–3.0. [29]. Accord-
ing to meta-analyses of atrial fibrillation or mixed popu-
lations assessing INR control and associated events [30],
more than half of all thromboembolic events occurred
when patients have an INR <2.0. Besides, the INR has a
safe range before surgical procedures. This “safe range”
is controversial because some experts recommended an
INR of ≤3 [17, 31], whereas others suggest an INR of ≤4
[32, 33] as safe for dental extractions. An INR above 5
has been shown to be an unacceptable risk for postoper-
ative bleeding [34]. However, none of the included pa-
tients had an INR of more than 5. Most of the patients
had an INR no higher than 4, as shown in Table 3. Next
to monitoring the INR, it is recommended to take a spe-
cial care of patients with renal dysfunction. Given the
renal excretion of drugs, renal dysfunction may result in
a higher incidence of bleeding associated with oral antic-
oagulation [35, 36]. A variety of local hemostatic mea-
sures are used in oral surgeries, including sutures, local
compression, adjuvants (such as fibrin and histoacryl
glue), local antifibrinolytic solutions, collagen fleeces,
acrylic splints, gelatin sponges and so on [37, 38]. Pla-
cing hemostatic, physiological or tranexamic acid
irrigation and mouthwash were used in our included
studies. However, one of the included studies [4] showed
that suturing played no significant role in bleeding sta-
tus. In their study, patients with sutures showed a higher
incidence of bleeding than patients without sutures. This
outcome might be caused by the mode of suturing that
further traumatizes the soft tissue. Four of the included
studies [7, 16, 21, 23] used local hemostatic measures,
except for local compression and sutures. The effective-
ness of these measures was worth studying.
Limitations
There were some limitations in the included studies.
Only one of the six included studies was judged to have
a low risk of bias, and the absence of randomization
may predispose the analysis to a risk of selection bias
and possible confounding effects [39]. Some studies were
carried out with limited patient numbers [21, 23] and, as
with all meta-analyses, there may be studies published in
other languages or unpublished studies that we were not
able to access. Additionally, the INR differed between
different studies which influenced the bleeding out-
comes. Patients with a low INR were less likely to suffer
bleeding than patients with a higher INR. Other factors,
such as gingival health, numbers and the complexity of
the tooth extractions, the surgical skills, anesthesia type,
material and suture technique, local hemostatic mea-
sures, and the use of anticoagulants differed from one
study to another or were not reported. This heterogen-
eity limited the scientific evidence that could be obtained
for this review.
Fig. 4 Forest plot of the difference of postoperative bleeding between OAT continued or discontinued group 1 day after the surgery
Fig. 5 Forest plot of the difference of postoperative bleeding between OAT continued or discontinued group 7 days after the surgery
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Conclusion
Under current studies and evidence, the results of our
meta-analysis revealed that patients continuing oral anti-
coagulant therapy do not increase the risk of bleeding after
dental extractions compared to patients who discontinue
oral anticoagulant therapy. However, with the limited num-
ber of included studies and the risk of bias, well-designed
RCTs should be included with a larger sample size as well
as specific inclusion and exclusion criteria. Moreover, it
would be better if the bleeding outcomes had a reporting
standard. This standardization would enhance the compar-
ability of studies based on identical outcome measure-
ments, which would help to establish guidelines for dentists
who treat these patients with complex medical needs.
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